Translational Neuroscience Program, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Translational Neuroscience Program, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Neuropharmacology. 2017 Sep 1;123:67-79. doi: 10.1016/j.neuropharm.2017.05.024. Epub 2017 May 25.
Amylin is produced in the pancreas and the brain, and acts centrally to reduce feeding and body weight. Recent data show that amylin can act in the ventral tegmental area (VTA) to reduce palatable food intake and promote negative energy balance, but the behavioral mechanisms by which these effects occur are not fully understood. The ability of VTA amylin signaling to reduce intake of specific palatable macronutrients (fat or carbohydrate) was tested in rats in several paradigms, including one-bottle acceptance tests, two-bottle choice tests, and a free-choice diet. Data show that VTA amylin receptor activation with the amylin receptor agonist salmon calcitonin (sCT) preferentially and potently reduces intake of fat, with more variable suppression of sucrose intake. Intake of a non-nutritive sweetener is also decreased by intra-VTA administration of sCT. As several feeding-related signals that act in the mesolimbic system also impact motivated behaviors besides feeding, we tested the hypothesis that the suppressive effects of amylin signaling in the VTA extend to other motivationally relevant stimuli. Results show that intra-VTA sCT reduces water intake in response to central administration of the dipsogenic peptide angiotensin II, but has no effect on ad libitum water intake in the absence of food. Importantly, open field and social interaction studies show that VTA amylin signaling does not produce anxiety-like behaviors. Collectively, these findings reveal a novel ability of VTA amylin receptor activation to alter palatable macronutrient intake, and also demonstrate a broader role of VTA amylin signaling for the control of motivated ingestive behaviors beyond feeding.
胰岛淀粉样多肽在胰腺和大脑中产生,在中枢发挥作用,减少摄食和体重。最近的数据表明,胰岛淀粉样多肽可以在腹侧被盖区(VTA)发挥作用,减少美味食物的摄入并促进负能平衡,但这些作用发生的行为机制尚不完全清楚。在几种范式中测试了 VTA 胰岛淀粉样多肽信号减少特定美味宏量营养素(脂肪或碳水化合物)摄入的能力,包括单瓶接受测试、双瓶选择测试和自由选择饮食。数据表明,VTA 胰岛淀粉样多肽受体激动剂鲑鱼降钙素(sCT)激活优先且有效地减少脂肪摄入,对蔗糖摄入的抑制更为多变。非营养性甜味剂的摄入也可通过 VTA 内给予 sCT 而减少。由于几种作用于中脑边缘系统的与摄食相关的信号除了摄食之外还会影响动机行为,我们测试了 VTA 中胰岛淀粉样多肽信号的抑制作用是否扩展到其他与动机相关的刺激的假设。结果表明,VTA 内的 sCT 减少了对中央给予血管紧张素 II 的水摄入,而在没有食物的情况下对随意饮水没有影响。重要的是,开放场和社会互动研究表明,VTA 胰岛淀粉样多肽信号不会产生焦虑样行为。总的来说,这些发现揭示了 VTA 胰岛淀粉样多肽受体激活改变美味宏量营养素摄入的新能力,并证明了 VTA 胰岛淀粉样多肽信号在控制除进食之外的动机性摄食行为方面的更广泛作用。